FDA Implements Automatic Detention on Kunming Aoqin Products!

Recently, the U.S. Food and Drug Administration (FDA) updated its import alert measures on its official website, implementing automatic detention on products from a certain company in China. Specific information is as follows:

• Alert Number: 45-02
• Release Date: December 2, 2024
• Region: Kunming, Yunnan
• Company Name: Kunming Aoqin Biotechnology Co., Ltd.
• Product Name: Dietary Supplement
• Testing Items: Tartrazine, Brilliant Blue, Erythrosine, Sunset Yellow

Import alerts are a preventive measure taken by the FDA against imported foods that pose potential risks. For companies or products listed under the import alert, the FDA will implement automatic detention (Detention Without Physical Examination, DWPE) without conducting an inspection. It is important to note that automatic detention does not equate to the product failing to meet U.S. import standards. Goods that are automatically detained must pass inspection by the FDA or an FDA-approved laboratory and receive approval from the local FDA office before customs will allow their release for sale in the U.S. market.